Indolinone based phosphoinositide-dependent kinase-1 (PDK1) inhibitors. Part 2: Optimization of BX-517
摘要:
Based on the lead compound BX-517, a series of C-4 ' substituted indolinones have been synthesized and evaluated for PDK1 inhibition. Modification at C-4 ' of the pyrrole afforded potent compounds (7b and 7d) with improved solubility and ADME properties. In this letter, we describe the synthesis, selectivity profile, and pharmacokinetic data of selected compounds. (C) 2007 Elsevier Ltd. All rights reserved.
Indolinone based phosphoinositide-dependent kinase-1 (PDK1) inhibitors. Part 2: Optimization of BX-517
摘要:
Based on the lead compound BX-517, a series of C-4 ' substituted indolinones have been synthesized and evaluated for PDK1 inhibition. Modification at C-4 ' of the pyrrole afforded potent compounds (7b and 7d) with improved solubility and ADME properties. In this letter, we describe the synthesis, selectivity profile, and pharmacokinetic data of selected compounds. (C) 2007 Elsevier Ltd. All rights reserved.
Indolinone derivatives and their use in treating disease-states such as cancer
申请人:Arnaiz Damian
公开号:US20050090541A1
公开(公告)日:2005-04-28
Indolinone derivatives, such as compounds of the formula (I):
wherein A, m, n, R
1
, R
2
, R
3
, R
5
and R
6
are described herein, are disclosed herein as being useful in treating mammal having disease-states alleviated by the inhibition of PDK-1 activity.
Indolinone based phosphoinositide-dependent kinase-1 (PDK1) inhibitors. Part 2: Optimization of BX-517
作者:Imadul Islam、Greg Brown、Judi Bryant、Paul Hrvatin、Monica J. Kochanny、Gary B. Phillips、Shendong Yuan、Marc Adler、Marc Whitlow、Dao Lentz、Mark A. Polokoff、James Wu、Jun Shen、Janette Walters、Elena Ho、Babu Subramanyam、Daguang Zhu、Richard I. Feldman、Damian O. Arnaiz
DOI:10.1016/j.bmcl.2007.05.060
日期:2007.7
Based on the lead compound BX-517, a series of C-4 ' substituted indolinones have been synthesized and evaluated for PDK1 inhibition. Modification at C-4 ' of the pyrrole afforded potent compounds (7b and 7d) with improved solubility and ADME properties. In this letter, we describe the synthesis, selectivity profile, and pharmacokinetic data of selected compounds. (C) 2007 Elsevier Ltd. All rights reserved.